WO2008008805A3 - Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes - Google Patents

Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes Download PDF

Info

Publication number
WO2008008805A3
WO2008008805A3 PCT/US2007/073202 US2007073202W WO2008008805A3 WO 2008008805 A3 WO2008008805 A3 WO 2008008805A3 US 2007073202 W US2007073202 W US 2007073202W WO 2008008805 A3 WO2008008805 A3 WO 2008008805A3
Authority
WO
WIPO (PCT)
Prior art keywords
target cells
toxins
clostridial
targeting activity
altered targeting
Prior art date
Application number
PCT/US2007/073202
Other languages
English (en)
Other versions
WO2008008805A2 (fr
Inventor
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Original Assignee
Allergan Inc
Lance E Steward
Joseph Francis
Ester Fernandez-Salas
Marcella A Gilmore
Shengwen Li
Kei Roger Aoki
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, Lance E Steward, Joseph Francis, Ester Fernandez-Salas, Marcella A Gilmore, Shengwen Li, Kei Roger Aoki filed Critical Allergan Inc
Priority to CA002657521A priority Critical patent/CA2657521A1/fr
Priority to AU2007272517A priority patent/AU2007272517B2/en
Priority to EP07812774A priority patent/EP2038299A2/fr
Priority to JP2009519645A priority patent/JP2009543558A/ja
Publication of WO2008008805A2 publication Critical patent/WO2008008805A2/fr
Publication of WO2008008805A3 publication Critical patent/WO2008008805A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des toxines clostridiennes modifiées qui comprennent un domaine enzymatique de toxine clostridienne, un domaine de translocation de toxine clostridienne, un domaine de facilitation de la translocation et un domaine cible modifié. L'invention concerne également des molécules polynucléotidiques qui codent pour de telles toxines clostridiennes modifiées et des procédés de production de telles toxines clostridiennes modifiées.
PCT/US2007/073202 2006-07-11 2007-07-11 Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes WO2008008805A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CA002657521A CA2657521A1 (fr) 2006-07-11 2007-07-11 Toxines clostridiennes modifiees a capacite de translocation amelioree et a activite modifiee de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes
AU2007272517A AU2007272517B2 (en) 2006-07-11 2007-07-11 Modified clostridial toxins with enhanced translocation capabilities and altered targeting activity for non-clostridial toxin target cells
EP07812774A EP2038299A2 (fr) 2006-07-11 2007-07-11 Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes
JP2009519645A JP2009543558A (ja) 2006-07-11 2007-07-11 増強した転位置能力および増強したターゲティング活性を有する改変クロストリジウム毒素

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80705906P 2006-07-11 2006-07-11
US60/807,059 2006-07-11

Publications (2)

Publication Number Publication Date
WO2008008805A2 WO2008008805A2 (fr) 2008-01-17
WO2008008805A3 true WO2008008805A3 (fr) 2008-04-10

Family

ID=38924120

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/073202 WO2008008805A2 (fr) 2006-07-11 2007-07-11 Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes

Country Status (5)

Country Link
EP (1) EP2038299A2 (fr)
JP (1) JP2009543558A (fr)
AU (1) AU2007272517B2 (fr)
CA (1) CA2657521A1 (fr)
WO (1) WO2008008805A2 (fr)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9617671D0 (en) * 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
US7192596B2 (en) 1996-08-23 2007-03-20 The Health Protection Agency Ipsen Limited Recombinant toxin fragments
EP2038298A2 (fr) * 2006-07-11 2009-03-25 Allergan, Inc. Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules cibles des toxines clostridiennes
US10240138B2 (en) 2008-06-12 2019-03-26 Ipsen Bioinnovation Limited Polypeptides that bind to and inhibit secretion from growth hormone secreting cells
US20110171191A1 (en) 2008-06-12 2011-07-14 Syntaxin Limited Suppression of neuroendocrine diseases
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
EP2406629B9 (fr) 2009-03-13 2014-03-26 Allergan, Inc. Dosages immunologiques de l'activité des endopeptidases reciblées
US20100303783A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases
US20100303791A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases
US8198229B2 (en) 2009-05-29 2012-06-12 Allergan, Inc. Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases
US20100303798A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases
US20100303789A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases
US20100303757A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Interleukin Retargeted Endopepidases
US20100303788A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases
US20100303756A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases
US20100303794A1 (en) * 2009-05-29 2010-12-02 Allergan, Inc. Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases
PT2528940E (pt) 2010-01-25 2014-06-24 Allergan Inc Métodos de conversão intracelular de proteínas de cadeia única na sua forma de cadeia dupla
ES2813650T3 (es) 2010-05-20 2021-03-24 Allergan Inc Toxinas clostridiales degradables
AU2011315962B2 (en) 2010-10-14 2016-06-02 Allergan, Inc. Targeted delivery of Targeted Exocytosis Modulators to the sphenopalatine ganglion for treatment of headache disorders
US20120244188A1 (en) 2011-03-25 2012-09-27 Allergan, Inc. Treatment of Sensory Disturbance Disorders
US20120251573A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Neuroendocrine Disorders
US20120251574A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase and Neurotoxin Combination Treatment of Multiple Medical Conditions
US20120251575A1 (en) 2011-03-28 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Involuntary Movement Disorders
US20120251518A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Sexual Dysfunction Disorders
US20120251519A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Smooth Muscle Disorders
US20120258132A1 (en) 2011-03-29 2012-10-11 Allergan, Inc. Vagal Nerve-Based Disorders
US20120251515A1 (en) 2011-03-29 2012-10-04 Allergan, Inc. Endopeptidase Treatment of Cosmesis Disorders
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
WO2012174123A1 (fr) 2011-06-13 2012-12-20 Allergan, Inc. Traitement de traumatismes psychologiques
US20130171122A1 (en) 2011-12-29 2013-07-04 Allergan, Inc. Endopeptidase and neurotoxin combination treatment of bladder disorders
US20140056870A1 (en) * 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
JP2015534814A (ja) * 2012-10-31 2015-12-07 イプセン バイオイノベーション リミテッド 組換えクロストリジウムボツリヌス神経毒
EP2934571B1 (fr) 2012-12-18 2018-05-30 Allergan, Inc. Traitement prophylactique de la récurrence de l'herpès
WO2016110662A1 (fr) 2015-01-09 2016-07-14 Ipsen Bioinnovation Limited Neurotoxines cationiques
JP2018525021A (ja) 2015-08-27 2018-09-06 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 疼痛の治療を目的とする組成物及び方法
MX2020007596A (es) 2018-01-29 2020-09-03 Ipsen Biopharm Ltd Neurotoxinas botulinicas para escindir una proteina de receptor de union a factor sensible a n-etilmaleimida soluble (snare) no neuronal.
US11975055B2 (en) 2018-05-21 2024-05-07 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
US20220016221A1 (en) 2018-12-05 2022-01-20 Ipsen Biopharm Limited Treatment of symptoms of traumatic brain injury
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
KR20230155007A (ko) 2021-03-30 2023-11-09 입센 바이오팜 리미티드 통증 ＆ 염증성 장애의 치료를 위한 촉매 불활성 클로스트리디움 신경독소
JP2024513191A (ja) 2021-03-30 2024-03-22 イプセン バイオファーム リミテッド 疼痛及び炎症性障害の処置
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site
WO2024069191A1 (fr) 2022-09-30 2024-04-04 Ipsen Biopharm Limited Neurotoxine clostridiale destinée à être utilisée dans un traitement de la cystite interstitielle
GB202404021D0 (en) 2024-03-20 2024-05-01 Ipsen Biopharm Ltd Cell-based neurotoxin assay

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (fr) * 1988-08-15 1990-03-21 Neorx Corporation Complexes covalents et méthodes pour cytotoxicité augmentée et pour imagerie
WO1998007864A1 (fr) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Fragments de toxines recombines
WO2001014570A1 (fr) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Neurotoxines de recombinaison activables
WO2004024909A2 (fr) * 2002-09-12 2004-03-25 Health Protection Agency Fragments de toxines recombines
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006099590A2 (fr) * 2005-03-15 2006-09-21 Allergan, Inc. Toxines de clostridiose modifiees presentant des capacites de ciblage modifiees pour des cellules cibles de toxine de clostridiose

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005279741B2 (en) * 2004-09-01 2011-10-06 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) * 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
EP2038298A2 (fr) * 2006-07-11 2009-03-25 Allergan, Inc. Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules cibles des toxines clostridiennes

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0359347A2 (fr) * 1988-08-15 1990-03-21 Neorx Corporation Complexes covalents et méthodes pour cytotoxicité augmentée et pour imagerie
WO1998007864A1 (fr) * 1996-08-23 1998-02-26 Microbiological Research Authority Camr (Centre For Applied Microbiology & Research) Fragments de toxines recombines
WO2001014570A1 (fr) * 1999-08-25 2001-03-01 Allergan Sales, Inc. Neurotoxines de recombinaison activables
WO2004024909A2 (fr) * 2002-09-12 2004-03-25 Health Protection Agency Fragments de toxines recombines
US20060024331A1 (en) * 2004-08-02 2006-02-02 Ester Fernandez-Salas Toxin compounds with enhanced membrane translocation characteristics
WO2006099590A2 (fr) * 2005-03-15 2006-09-21 Allergan, Inc. Toxines de clostridiose modifiees presentant des capacites de ciblage modifiees pour des cellules cibles de toxine de clostridiose

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2038299A2 *

Also Published As

Publication number Publication date
AU2007272517A1 (en) 2008-01-17
AU2007272517B2 (en) 2013-09-26
JP2009543558A (ja) 2009-12-10
WO2008008805A2 (fr) 2008-01-17
EP2038299A2 (fr) 2009-03-25
CA2657521A1 (fr) 2008-01-17

Similar Documents

Publication Publication Date Title
WO2008008805A3 (fr) Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules qui ne sont pas cibles des toxines clostridiennes
WO2008008803A3 (fr) Toxines clostridiennes modifiées à capacité de translocation améliorée et à activité modifiée de ciblage des cellules cibles des toxines clostridiennes
WO2008105901A3 (fr) Toxines clostridiennes modifiées ayant une capacité de translocation augmentée et une activité de ciblage augmentée
WO2006099590A3 (fr) Toxines de clostridiose modifiees presentant des capacites de ciblage modifiees pour des cellules cibles de toxine de clostridiose
ATE463506T1 (de) Mit clostriedientoxin aktivierbare clostridientoxine
ATE416191T1 (de) Abbaubare clostridientoxine
MX369263B (es) Toxinas de clostridium degradables.
JP2009508489A5 (fr)
WO2006124999A3 (fr) Procede de production du resveratrol dans une cellule hote bacterienne recombinante
WO2008053232A3 (fr) Composition de réduction de la mycotoxine
WO2006043178A3 (fr) Enzymes et procedes
EP4285909A3 (fr) Utilisation du hsp70 en tant que régulateur de l'activité enzymatique
WO2008073446A3 (fr) Procédés et systèmes relatifs à la transmission d'informations associées à des nutraceutiques
WO2008033830A3 (fr) Codage avec conscience de complexité
WO2010014632A3 (fr) Procédés et compositions permettant d'améliorer la production de certains produits dans des micro-organismes
MX2010003194A (es) Variantes de glucoamilasa con propiedades alteradas.
WO2006102652A3 (fr) Expression de glycosyltransferases eucaryotiques solubles, actives dans des organismes procaryotiques
WO2010138395A3 (fr) Procédés de traitement d'une inflammation neurogène chronique à l'aide d'endopeptidases reciblées contre les hormones de type glucagon
WO2008054821A3 (fr) Protéines hydrolase mutantes à cinétique et expression fonctionnelle améliorées
WO2010014631A3 (fr) Procédés et compositions permettant d'améliorer la production de certains produits dans des micro-organismes
WO2010138379A3 (fr) Procédés de traitement d'inflammation neurogénique chronique par le biais d'endopeptidases à reciblage de galanine
WO2008061256A3 (fr) Utilisation de poursuite d'un dispositif multimédia portable
WO2010138393A3 (fr) Procédés de traitement de troubles urogénitaux-neurologiques à l'aide d'endopeptidases reciblées contre les hormones de type glucagon
WO2010138387A3 (fr) Procédés de traitement d'inflammation neurogénique chronique par le biais d'endopeptidases à reciblage d'interleukine
WO2010138392A3 (fr) Procédés de traitement d'une inflammation neurogénique chronique à l'aide d'endopeptidases reciblées contre les neurotrophines

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07812774

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 2657521

Country of ref document: CA

REEP Request for entry into the european phase

Ref document number: 2007812774

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007272517

Country of ref document: AU

Ref document number: 2007812774

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009519645

Country of ref document: JP

ENP Entry into the national phase

Ref document number: 2007272517

Country of ref document: AU

Date of ref document: 20070711

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: RU

REG Reference to national code

Ref country code: BR

Ref legal event code: B01E

Ref document number: PI0715456

Country of ref document: BR

Free format text: APRESENTE FOLHAS DO RELATORIO DESCRITIVO E DO DESENHO ADAPTADOS AO AN NO127/1997.

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0715456

Country of ref document: BR

Free format text: PEDIDO RETIRADO POR NAO CUMPRIMENTO DA EXIGENCIA FORMULADA NA RPI 2200 DE 05/03/2013